Joshua R Menke, MD
Pathology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 2
- Since medical school
- 15 years
- University of Florida College of Medicine, 2011
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Menke’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A126371 · Current
Licensed to practise in California · since 2013 · expires 2027-07-31 · University of Florida College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$59,295
Medicare paid this office $59,295 for 395 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 237 | $17,944 | $73 |
| Special stained specimen slides to examine tissue, each additional procedure | 65 | $8,623 | $25 |
| Pathology examination of tissue using a microscope, intermediate complexity | 139 | $7,131 | $33 |
| Bone marrow, smear interpretation | 134 | $5,746 | $42 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 91 | $5,520 | $56 |
See all 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 237 | $17,944 | $73 |
| Special stained specimen slides to examine tissue, each additional procedure | 65 | $8,623 | $25 |
| Pathology examination of tissue using a microscope, intermediate complexity | 139 | $7,131 | $33 |
| Bone marrow, smear interpretation | 134 | $5,746 | $42 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 91 | $5,520 | $56 |
| Special stained specimen slides to examine tissue, initial procedure | 75 | $2,729 | $31 |
| Microscopic genetic analysis of tumor, manual | 46 | $2,464 | $37 |
| Genetic sequencing localization, initial procedure | 44 | $1,724 | $37 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 21 | $1,424 | $68 |
| Preparation of tissue for examination by removing any calcium present | 127 | $1,394 | $11 |
| Genetic sequencing localization, each additional procedure | 33 | $1,056 | $30 |
| Special stained specimen slides to examine tissue including interpretation and report | 57 | $772 | $11 |
| Cell examination of specimen, concentration technique | 34 | $645 | $18 |
| Blood smear interpretation by physician with written report | 20 | $452 | $22 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Fine needle aspiration biopsy, first growth | 12 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
395 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 11% · Women 48% · Also on Medicaid 19% · Health risk score 2.31. Above the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 73% · Coronary heart disease 37% · Chronic kidney disease 36% · Diabetes 34% · Atrial fibrillation 26% · Heart failure 24% · Cancer 22% · Depression 22% · COPD 15% · Dementia 14% · Stroke 14%.
The office billed $616,310, Medicare allowed $75,743 and paid $59,295; for 1,606 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 395 | 1,606 | 74 | 2.31 | $616,310 | $59,295 |
| 2023 | 396 | 1,579 | 74 | 2.18 | $549,486 | $62,562 |
| 2022 | 288 | 1,074 | 74 | 2.24 | $314,154 | $40,231 |
| 2021 | 244 | 1,010 | 74 | 2.21 | $269,175 | $37,242 |
| 2020 | 112 | 474 | 71 | 1.97 | $118,497 | $18,055 |
| 2019 | 15 | 16 | 70 | 1.38 | $4,393 | $686 |
| 2018 | 32 | 32 | 66 | 1.55 | $10,176 | $1,857 |
| 2016 | 277 | 920 | 71 | 1.81 | $153,944 | $41,093 |
| 2015 | 236 | 792 | 70 | 1.46 | $136,933 | $35,339 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 233 | $18,297 | $74 |
| Pathology examination of tissue using a microscope, intermediate complexity | 160 | $7,770 | $34 |
| Bone marrow, smear interpretation | 152 | $7,016 | $44 |
| Special stained specimen slides to examine tissue, each additional procedure | 53 | $6,305 | $26 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 82 | $5,595 | $57 |
| Microscopic genetic analysis of tumor, manual | 57 | $3,345 | $39 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 41 | $3,117 | $74 |
| Special stained specimen slides to examine tissue, initial procedure | 71 | $2,405 | $32 |
| Genetic sequencing localization, initial procedure | 51 | $2,089 | $40 |
| Preparation of tissue for examination by removing any calcium present | 149 | $1,770 | $11 |
| Genetic sequencing localization, each additional procedure | 40 | $1,333 | $32 |
| Special stained specimen slides to examine tissue including interpretation and report | 61 | $889 | $11 |
| Cell examination of specimen, concentration technique | 31 | $711 | $21 |
| Blood smear interpretation by physician with written report | 19 | $513 | $22 |
2022: 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 130 | $9,919 | $72 |
| Special stained specimen slides to examine tissue, each additional procedure | 47 | $5,663 | $26 |
| Bone marrow, smear interpretation | 100 | $4,211 | $41 |
| Pathology examination of tissue using a microscope, intermediate complexity | 101 | $3,644 | $34 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 35 | $2,582 | $74 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 41 | $2,544 | $58 |
| Microscopic genetic analysis of tumor, manual | 38 | $2,410 | $39 |
| Special stained specimen slides to examine tissue, initial procedure | 54 | $1,879 | $32 |
| Genetic sequencing localization, initial procedure | 36 | $1,476 | $40 |
| Cell examination of specimen, concentration technique | 49 | $1,092 | $20 |
| Preparation of tissue for examination by removing any calcium present | 92 | $1,069 | $11 |
| Genetic sequencing localization, each additional procedure | 26 | $932 | $32 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 11 | $887 | $81 |
| Special stained specimen slides to examine tissue including interpretation and report | 39 | $594 | $11 |
2021: 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 123 | $9,879 | $66 |
| Special stained specimen slides to examine tissue, each additional procedure | 46 | $4,886 | $27 |
| Bone marrow, smear interpretation | 87 | $4,114 | $45 |
| Pathology examination of tissue using a microscope, intermediate complexity | 92 | $3,703 | $36 |
| Microscopic genetic analysis of tumor, manual | 48 | $3,097 | $40 |
| Special stained specimen slides to examine tissue, initial procedure | 56 | $1,982 | $34 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 22 | $1,590 | $72 |
| Genetic sequencing localization, initial procedure | 32 | $1,375 | $42 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 20 | $1,129 | $56 |
| Preparation of tissue for examination by removing any calcium present | 89 | $1,089 | $12 |
| Cell examination of specimen, concentration technique | 45 | $1,081 | $21 |
| Genetic sequencing localization, each additional procedure | 26 | $930 | $33 |
| Special stained specimen slides to examine tissue including interpretation and report | 37 | $678 | $11 |
| Blood smear interpretation by physician with written report | 15 | $300 | $20 |
2020: 12 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 45 | $3,889 | $81 |
| Special stained specimen slides to examine tissue, each additional procedure | 20 | $3,243 | $27 |
| Bone marrow, smear interpretation | 32 | $1,509 | $47 |
| Pathology examination of tissue using a microscope, intermediate complexity | 37 | $1,466 | $37 |
| Microscopic genetic analysis of tumor, manual | 20 | $1,427 | $41 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 19 | $1,281 | $61 |
| Special stained specimen slides to examine tissue, initial procedure | 28 | $1,060 | $34 |
| Genetic sequencing localization, initial procedure | 17 | $846 | $42 |
| Cell examination of specimen, concentration technique | 23 | $656 | $22 |
| Genetic sequencing localization, each additional procedure | 12 | $600 | $33 |
| Preparation of tissue for examination by removing any calcium present | 33 | $397 | $12 |
| Special stained specimen slides to examine tissue including interpretation and report | 11 | $267 | $12 |
2019: 1 service
| Fine needle aspiration biopsy, first growth | 12 | $444 | $37 |
2018: 1 service
| Fine needle aspiration biopsy, first growth | 32 | $1,857 | $58 |
2016: 8 services
| Pathology examination of tissue using a microscope, intermediate complexity | 139 | $11,889 | $32 |
| Pathology examination of tissue using a microscope, moderately high complexity | 76 | $9,494 | $72 |
| Pathology examination of specimen during surgery, first tissue block | 81 | $9,129 | $54 |
| Pathology examination of tissue using a microscope, high complexity | 45 | $5,888 | $125 |
| Special stained specimen slides to examine tissue, each additional procedure | 20 | $1,399 | $23 |
| Special stained specimen slides to examine tissue, initial procedure | 26 | $857 | $31 |
| Pathology examination of specimen during surgery, each additional tissue block | 11 | $716 | $27 |
| Pathology examination of tissue using a microscope, moderately low complexity | 30 | $389 | $10 |
2015: 9 services
| Pathology examination of tissue using a microscope, intermediate complexity | 109 | $9,707 | $32 |
| Pathology examination of tissue using a microscope, moderately high complexity | 66 | $8,721 | $71 |
| Pathology examination of specimen during surgery, first tissue block | 64 | $6,593 | $53 |
| Pathology examination of tissue using a microscope, high complexity | 50 | $6,266 | $125 |
| Special stained specimen slides to examine tissue, initial procedure | 28 | $1,053 | $30 |
| Special stained specimen slides to examine tissue, each additional procedure | 19 | $774 | $18 |
| Pathology examination of specimen during surgery, each additional tissue block | 11 | $657 | $26 |
| Pathology examination of tissue using a microscope, moderately low complexity | 25 | $283 | $9 |
| Pathology examination of tissue using a microscope, limited examination | 13 | $50 | $4 |
Medicaid work
$13,741 in 2024
Medicaid paid $13,741 for 397 billed services this clinician did in 2024, up to 44 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Bone marrow, smear interpretation | 61 | $3,563 |
| TISSUE EXAM BY PATHOLOGIST | 47 | $2,495 |
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 89 | $2,121 |
| Blood smear, peripheral, interpretation by physician with written report | 104 | $1,750 |
| Flow cytometry, interpretation; 9 to 15 markers | 27 | $1,585 |
| Flow cytometry, interpretation; 16 or more markers | 14 | $987 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 13 | $799 |
| DECALCIFICATION PROCEDURE | 42 | $442 |
| 2024 | 397 | 8 | 44 | $13,741 |
| 2023 | 397 | 6 | 31 | $10,048 |
| 2022 | 151 | 5 | 23 | $3,293 |
| 2021 | 89 | 5 | 15 | $1,846 |
| 2020 | 59 | 3 | 26 | $1,735 |
| 2018 | 12 | 1 | 12 | $63 |
See the largest Medicaid services in earlier years
2023
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 110 | $2,589 |
| Bone marrow, smear interpretation | 65 | $2,544 |
| TISSUE EXAM BY PATHOLOGIST | 50 | $1,643 |
| Flow cytometry, interpretation; 16 or more markers | 30 | $1,615 |
| Blood smear, peripheral, interpretation by physician with written report | 111 | $1,498 |
| DECALCIFICATION PROCEDURE | 31 | $159 |
2022
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 87 | $1,701 |
| Flow cytometry, interpretation; 16 or more markers | 13 | $689 |
| Bone marrow, smear interpretation | 19 | $472 |
| Blood smear, peripheral, interpretation by physician with written report | 20 | $225 |
| TISSUE EXAM BY PATHOLOGIST | 12 | $205 |
2021
| Flow cytometry, interpretation; 16 or more markers | 14 | $657 |
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 33 | $602 |
| Bone marrow, smear interpretation | 16 | $334 |
| TISSUE EXAM BY PATHOLOGIST | 13 | $211 |
| DECALCIFICATION PROCEDURE | 13 | $41 |
2020
| Flow cytometry, interpretation; 16 or more markers | 15 | $792 |
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 32 | $708 |
| Bone marrow, smear interpretation | 12 | $235 |
2018
| Fine needle aspiration biopsy, without imaging guidance; first lesion | 12 | $63 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1528353786
- Licence
- CA A126371California A126371: Current · expires 2027-07-31
- Trained
- University of Florida College of Medicine, 2011 · 15 years ago
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZC0500X (207ZC0500X); Federal specialty code 207ZH0000X (207ZH0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-06-16
- NPI last updated
- 2024-03-14
- NPI record certified
- 2024-03-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 200 1st St Sw, Rochester, MN, 55905